Why is Tango Therapeutics stock sliding today?

Tango Therapeutics stock fell 6.8% in pre-open trading today after the company released its Phase 1/2 clinical trial results at the European Society for Medical Oncology Congress in Madrid and simultaneously hosted a PDAC-focused investor webcast at 7:30 am ET. Despite the headline data showing an 82% objective response rate and an 88% nine-month progression-free survival rate in previously treated patients with MTAP-deleted, RAS-mutant pancreatic cancer, the market response has been a sharp pullback consistent with a "sell the news" dynamic.

The decline is best understood in the context of the stock’s recent run-up: shares had climbed from around $21.89 on October 13 to a previous close of $27.93 — a gain of roughly 28% — as investors accumulated positions ahead of the ESMO data event. With the catalyst now in the market and a Phase 3 trial not expected to begin until the first half of 2027, near-term traders appear to be locking in gains. Adding to the selling pressure, an affiliate officer filed a Rule 144 notice to sell up to 15,231 shares through Morgan Stanley, a disclosure that can weigh on sentiment even when such sales are pre-planned.

The broader market backdrop is not helping. Thursday’s session saw a sharp technology-led sell-off, with the Nasdaq suffering its worst day since June and the S&P 500 posting its worst session since July. Futures remained under pressure heading into today’s pre-market, with the S&P 500 edging down 0.2% and the Nasdaq off modestly, reflecting lingering concerns about the sustainability of AI-related spending and broader risk appetite.

Taken together, a fully priced-in clinical catalyst, modest insider selling pressure, and a fragile macro backdrop have combined to push TNGX lower in pre-market trading, even as the underlying trial data — and the company’s plan to advance to a front-line Phase 3 study — remain broadly encouraging for the longer-term investment case.